https://www.thebodypro.com/author/treatment-action-group

Latest by Treatment Action Group

Ending the Epidemic Without Medicaid Expansion? Img
News

Ending the Epidemic Without Medicaid Expansion?

With Louisiana being the only state in the Deep South that has expanded Medicaid to date, are "End the Epidemic" strategies realistic in the southern U.S.?

Additional Remission Cases Published Img

Additional Remission Cases Published

Two recent case reports of temporary HIV remission, first presented at this year's CROI and IAS conferences, have now been published in the open access journal _PLoS Medicine_.

HIV Latency: Trapped in Transition, Lurking in Treg Img

HIV Latency: Trapped in Transition, Lurking in Treg

New research supports the theory that HIV latency occurs when HIV infects a CD4 T cell that is in the process of transitioning from an activated state to a resting state.

Locking Down Latent HIV Img

Locking Down Latent HIV

Researchers are flipping the idea of latency reversal on its head. Their approach -- which they have dubbed block and lock -- involves trying to imprison latent HIV in a way that prevents it from ever reactivating.

Estimating the Total Size of the HIV Reservoir Img

Estimating the Total Size of the HIV Reservoir

Researchers estimated a total body burden of as many as seven million cells expressing HIV RNA at any given time in tissues, despite viral load suppression to undetectable levels in the blood.

Effects of the Anti-Inflammatory Antibody Canakinumab on Heart Disease and Cancer: Implications for HIV? Img

Effects of the Anti-Inflammatory Antibody Canakinumab on Heart Disease and Cancer: Implications for HIV?

New study results prompt the question of whether canakinumab or other anti-inflammatories could have salutary clinical effects in HIV-positive people.

Report From the 2017 IAS HIV Cure and Cancer Forum Img
Cancer

Report From the 2017 IAS HIV Cure and Cancer Forum

Many approaches being pursued as cancer therapeutics are also being studied in the context of HIV cure research, including immune checkpoint inhibitors, cytokine therapies, genetically modified chimeric antigen receptor (CAR) T cells and other gene t...

Mosaic Antigens and Mountaineering Metaphors: Climbing Toward the Next HIV Vaccine Efficacy Trial Img
IAS (International AIDS Society) Conference

Mosaic Antigens and Mountaineering Metaphors: Climbing Toward the Next HIV Vaccine Efficacy Trial

Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.

HIV Remission News From IAS 2017 Img
IAS (International AIDS Society) Conference

HIV Remission News From IAS 2017

Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort Img

Evidence of Smaller HIV Reservoirs in a Ugandan Cohort

Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.